Faheem Hasnain

Mr. Hasnain is the Co-Founder, Chairman, CEO and President of Gossamer Bio and Chairman of Mirati Therapeutics. Previously, Mr. Hasnain served as President, Chief Executive Officer and a Director of Receptos, Inc (acquired by Celgene Corporation). Prior to joining Receptos, Mr. Hasnain was the President and Chief Executive Officer and a Director of Facet Biotech Corporation (acquired by Abbott). Previously, Mr. Hasnain was President, Chief Executive Officer and a Director of PDL BioPharma, Inc. Mr. Hasnain served as Executive Vice President in charge of the oncology/rheumatology strategic business unit at Biogen Idec Inc. Prior to Biogen Idec, Mr. Hasnain held roles with Bristol Myers Squibb, where he was President of the Oncology Therapeutics Network, and for 14 years at GlaxoSmithKline and its predecessor organizations. He serves as Chairman of the Board of Sente, Inc., a member of the Board of Directors at Kura Oncology, and a member of the Board of Overseers of Scripps Research Institute. He previously served as Chairman of the Board of Tocagen, Inc., Ambit Biosciences Corporation and served as a member of the Board of Directors of Tercica, Inc., Aragon Pharmaceuticals, Inc., Seragon Pharmaceuticals, Inc., Somaxon Pharmaceuticals, Inc., and Vital Therapies, Inc. He has also serves as an advisor to Temasek’s Vertex Fund. Mr. Hasnain received a BHK and BEd from the University of Windsor Ontario in Canada.